Facing a difficult 2023 biotech market, Recludix pursued both venture financing and a strategic partnership simultaneously. The company ultimately chose the non-dilutive Sanofi deal, highlighting the immense value of a 50-50 US profit-sharing option on a potential blockbuster asset, which was deemed superior to taking venture funding.

Eli Lilly's deal chief revealed that even premium acquisition offers are frequently rebuffed by public biotech companies without negotiation. This highlights a significant valuation gap where biotech boards believe their assets are worth far more than what even well-capitalized buyers like Lilly are willing to pay, stalling potential M&A activity.

Major pharmaceutical companies are committing to bio-buck deals worth billions for unproven, preclinical assets. The Sanofi-Irindale deal ($2.56B potential) and the Pfizer-Cartography deal ($850M+ potential) for discovery-stage programs show a high appetite for risk when accessing innovative technology platforms and novel targets early on.

Major firms like Merck employ varied deal structures to build pipelines. Merck's $6.7 billion all-upfront acquisition of Terns for a Phase 1-2 asset contrasts with its Quotient collaboration, which has a small $20 million upfront but $2.2 billion in discovery-stage milestones. This highlights a flexible approach to risk and reward.

Instead of specific financial guidance, Regeneron's management uses qualitative phrases like "pipeline in a molecule." Given their history of drastically outperforming early sales estimates (e.g., Dupixent's $2B initial estimate vs. $20B reality), this vague language is a credible signal of significant upside that analysts often miss.

Sanofi announced three significant collaborations in just one week with Indupro, Adel, and Drenbio. This rapid-fire deal-making underscores a concentrated strategic effort to build a leading pipeline in autoimmune and neurodegenerative diseases by acquiring innovative, early-stage assets like bispecific antibodies and tau-targeting MABs.

Strategic investors like Sanofi and AbbVie invest in early-stage biotechs not just for financial return, but to monitor disruptive technologies. This gives them a seat at the table to observe innovations that could render their own multi-billion dollar franchises obsolete in the next decade.

New Sanofi CEO Belain Garijo is signaling a fundamental R&D overhaul focused on fixing the company's struggling pipeline. Her comments about deeply reviewing the 'late stage portfolio' and not having a 'target number of products to discontinue' suggest a ruthless culling process is underway to de-risk the pipeline and find a true successor to the blockbuster Dupixent.

Neurix's deals with Sanofi and Gilead involve the partner funding early development through human proof-of-concept, minimizing Neurix's upfront financial risk. Crucially, the deal structure allows Neurix to "opt-in" for a 50/50 profit share in the U.S. later, retaining significant upside on successful programs.